Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide in treating metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. The phase 2 trial demonstrated that tirzepatide, in varying dosages, successfully met the primary endpoint, with a substantial percentage of participants achieving MASH resolution without worsening fibrosis after […]
Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial for olomorasib, showcasing significant advancements in the treatment of advanced solid tumors with KRAS G12C mutations. The data, which highlights both monotherapy and combination therapy results with Merck’s KEYTRUDA (pembrolizumab), was presented at the prestigious 2024 American […]
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly enhance its oncology portfolio. The deal, initially announced in January 2019, marks a pivotal step in Lilly’s strategy to focus on precision medicines tailored for cancers driven by specific gene […]
Eli Lilly and Company (Lilly), a global leader in pharmaceuticals, has made headlines with its announcement to acquire Loxo Oncology, a pioneering biopharmaceutical company based in Stamford, Connecticut. The all-cash deal, valued at $8 billion, is poised to significantly enhance Lilly’s oncology portfolio by integrating Loxo Oncology’s cutting-edge precision medicines. A strategic move in oncology […]
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy for adults. The approval marks a significant milestone for Lilly, as Emgality becomes available as a once-monthly, self-administered, subcutaneous injection designed to help prevent migraines. Emgality, a calcitonin gene-related peptide […]
Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology company, for $1.6 billion. This move is part of Lilly’s strategic initiative to enhance its immuno-oncology program, one of the most promising areas in cancer research today. Details of the […]
Lilly gastric cancer drug Cyramza (ramucirumab) did meet the primary endpoint of a phase 3 trial RAINFALL but could not improve overall survival of patients.
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma achieved mixed results. While the trial met its primary endpoint of progression-free survival (PFS), it did not improve overall survival (OS), a key […]
Eli Lilly and Company (Lilly) has bagged the abemaciclib FDA approval to treat advanced breast cancer in patients whose breast cancer had progressed after taking therapy that changed their hormones (endocrine therapy).
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer who have seen progression after previous treatment. This recent approval allows for the use of Verzenio in combination with fulvestrant in patients whose cancer has advanced on endocrine therapy. Detailed […]
